NEOG News & Events

Zoetis (ZTS) announced it has entered into a definitive agreement with Neogen (NEOG) to acquire Neogen's animal genomics business for $160M, subject to customary closing adjustments. The deal is subject to customary closing conditions and the satisfaction of regulatory requirements, and Zoetis expects to complete the acquisition in the second half of calendar year 2026.

Neogen is voluntarily recalling all lots within expiry of Neogen Vet Hycoat Hyaluronate Sodium Sterile Solution, for use in dogs, cats, and horses, to the veterinarian level. Neogen distributes this product, which is manufactured by a third-party supplier. This recall has been initiated due to microbial contamination in certain lots of 10 mL/50 mg product vials. Neogen received a number of reports of adverse events in horses following intraarticular injections of this product, which is inconsistent with its labeled, intended use. To date, Neogen has not received reports of adverse events when used in a manner consistent with the labeled use. While the company's investigation into this issue is ongoing, out of an abundance of caution the 2mL/20mg product vials are also being recalled. The company is proactively working with the FDA on this matter. This product is labeled as a sterile solution, but due to microbial contamination of certain lots, the recalled lots should no longer be considered sterile. The risk is particularly acute when used as an intraarticular injection, inconsistent with its labeled, intended use. No other Neogen products are affected by this field action.